StartsideRARE • NASDAQ
add
Ultragenyx Pharmaceutical Inc
Forrige sluttkurs
43,65 $
Dagsintervall
41,58 $ - 43,72 $
Årsintervall
37,02 $ - 60,37 $
Markedsverdi
3,88 mrd. USD
Gjennomsnittlig volum
812,68k
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Omsetning | 139,49 mill. | 42,27 % |
Driftskostnader | 250,46 mill. | 7,88 % |
Nettoomsetning | −133,52 mill. | 16,37 % |
Netto resultatmargin | −95,71 | 41,22 % |
Fortjeneste per aksje | −1,40 | 37,22 % |
EBITDA | −123,23 mill. | 10,64 % |
Faktisk avgiftssats | −0,23 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 607,51 mill. | 37,42 % |
Totale aktiva | 1,54 mrd. | 24,25 % |
Totale passiva | 1,18 mrd. | −1,81 % |
Total egenkapital | 353,83 mill. | — |
Utestående aksjer | 92,28 mill. | — |
P/B-forhold | 11,61 | — |
Avkastning på aktiva | −20,90 % | — |
Avkastning på kapital | −25,14 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | −133,52 mill. | 16,37 % |
Kontantstrøm fra drift | −67,00 mill. | 43,16 % |
Kontanter fra investering | −275,50 mill. | −528,50 % |
Kontanter fra finansiering | 11,17 mill. | −55,72 % |
Netto kontantstrøm | −330,05 mill. | −1 035,71 % |
Fri kontantstrøm | −23,26 mill. | 65,84 % |
Om
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Administrerende direktør
Grunnlagt
2010
Hovedkvarter
Nettsted
Ansatte
1 276
